Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 1,694 trials

Spinal Muscular Atrophy: Risdiplam Study for Infants

We are investigating how the medication risdiplam works and its safety in infants with spinal muscular atrophy. This study aims to provide important insights into its use for this condition.

Spinal Muscular Atrophy1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Posaconazole for Young Children with Fungal Infections

We are studying how well Posaconazole works and its safety in children under 2 years old with invasive fungal infections. This research will help us understand its effects compared to older patients.

Fungal Infection3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPediatrics

Richter's Syndrome: M-CHOP with Mosunetuzumab

We are studying a new treatment combining mosunetuzumab with CHOP for patients with Richter's Syndrome who have not had therapy before. The aim is to evaluate its effectiveness and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Chronic Kidney Disease: Patiromer Study

We are testing whether patiromer helps patients with chronic kidney disease better manage their blood pressure and reduce protein in urine. This study aims to improve treatment options for those with advanced kidney disease.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyNephrology

Cholangiocarcinoma: Tinengotinib Study

We are studying the safety and effectiveness of a new oral medication, tinengotinib, for patients with FGFR-altered cholangiocarcinoma that hasn't responded to other treatments. This trial compares tinengotinib to the physician's choice of treatment.

Cholangiocarcinoma6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Prostate Cancer: Abiraterone and Oxycodone Study

We are investigating how abiraterone affects the metabolism of oxycodone in men with prostate cancer. This may help improve pain management for patients using these medications.

Prostate Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology

End-Stage Renal Disease: Rivaroxaban Dosing Study

We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.

Chronic Hemodialysis≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Graft-versus-Host Disease: MC0518 Treatment Study

We are testing a new treatment, MC0518, for adults and adolescents with steroid-refractory acute graft-versus-host disease after stem cell transplantation. The study aims to see if it works better than the best available therapy and how it affects patients' quality of life.

Steroid Refractory Acute Graft Versus Host DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Early Breast Cancer: Elacestrant and Ribociclib Study

We are testing a new treatment combination of elacestrant and ribociclib for patients with hormone-sensitive early breast cancer. The goal is to see if this combination works better than standard therapies before surgery.

Hormone Receptor Positive HER2 Negative Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Hereditary Angioedema: PHA-022121 Treatment Study

We are testing the safety of a new oral medication for treating acute angioedema attacks in patients with hereditary angioedema. The study will also evaluate how well it relieves symptoms during these attacks.

Hereditary AngioedemaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Cardiovascular Disease: New Care Strategies for Type 1 Diabetes

We are testing a new care approach to reduce cardiovascular disease risk in people with type 1 diabetes. This study also evaluates the safety of a medication called finerenone in this high-risk group.

Type 1 Diabetes>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Nonsegmental Vitiligo: Ritlecitinib Study

We are investigating the safety and effectiveness of ritlecitinib in adults and adolescents with nonsegmental vitiligo. This study looks at how well the medication works over time for those who have already been treated.

Non-Segmental Vitiligo1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

UveitisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Hidradenitis Suppurativa: New Antibiotic Treatment Study

We are evaluating a new antibiotic regimen for people with Hurley stage 2 Hidradenitis Suppurativa to see if it works better than standard treatment. The study will also look at pain relief and quality of life improvements.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyInfectious Diseases

Lupus Nephritis: Obinutuzumab for Adolescents

We are studying the effects of obinutuzumab in adolescents with active lupus nephritis to see if it is more effective than a placebo. The trial also includes younger children to evaluate safety and how the drug works in them.

Lupus Nephritis>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteNephrologyPediatricsRheumatology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology